Lactosylated PLGA nanoparticles containing ϵ-polylysine for the sustained release and liver-targeted delivery of the negatively charged proteins

Zhou, Ping; An, Tong; Zhao, Chuan; Li, Yuan; Li, Rongshan; Yang, Rui; Wang, Yinsong; Gao, Xiujun

doi:10.1016/j.ijpharm.2014.12.017

Cited by 22 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Various studies have also demonstrated that Tween 80-based NPs could inhibit the exocytosis of p-gp, increasing the concentration of chemotherapeutics in tumor cells. 32 In this study, PLGA-Tween 80 conjugate was first synthesized via a one-step esterification reaction.…”

Section: Results and Discussion Characterization Of Synthesized Copolmentioning

confidence: 99%

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

Ji¹,

Chen²,

Bao³

et al. 2016

IJN

View full text Add to dashboard Cite

Drug resistance has become a main obstacle for the effective treatment of lung cancer. To address this problem, a novel biocompatible nanoscale package, poly( d , l -lactide- co -glycolide)-Tween 80, was designed and synthesized to overcome paclitaxel (PTX) resistance in a PTX-resistant human lung cancer cell line. The poly( d , l -lactide-co-glycolide) (PLGA)-Tween 80 nanoparticles (NPs) could efficiently load PTX and release the drug gradually. There was an increased level of uptake of PLGA-Tween 80 in PTX-resistant lung cancer cell line A549/T, which achieved a significantly higher level of cytotoxicity than both PLGA NP formulation and Taxol ® . The in vivo antitumor efficacy also showed that PLGA-Tween 80 NP was more effective than Taxol ® , indicating that PLGA-Tween 80 copolymer was a promising carrier for PTX in resistant lung cancer.

show abstract

Section: Results and Discussion Characterization Of Synthesized Copolmentioning

confidence: 99%

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

Ji¹,

Chen²,

Bao³

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…TWI, WT, and HET animals (PND 19 to 21) were used for experiments. TWI animals were intraperitoneally injected with NPs (1600 mg/kg) or with free GALC (100 mg/kg) diluted in 1 ml of physiological solution ( 3 , 47 ). After 4 hours, mice were deeply anesthetized with a urethane solution (0.8 ml/Hg; Sigma-Aldrich) and euthanized by transcardial perfusion with PBS so as to remove the blood from vessels.…”

Section: Methodsmentioning

confidence: 99%

Brain-targeted enzyme-loaded nanoparticles: A breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease

et al. 2019

View full text Add to dashboard Cite

Lysosomal storage disorders (LSDs) result from an enzyme deficiency within lysosomes. The systemic administration of the missing enzyme, however, is not effective in the case of LSDs with central nervous system (CNS)-involvement. Here, an enzyme delivery system based on the encapsulation of cross-linked enzyme aggregates (CLEAs) into poly-(lactide-co-glycolide) (PLGA) nanoparticles (NPs) functionalized with brain targeting peptides (Ang2, g7 or Tf2) is demonstrated for Krabbe disease, a neurodegenerative LSD caused by galactosylceramidase (GALC) deficiency. We first synthesize and characterize Ang2-, g7- and Tf2-targeted GALC CLEA NPs. We study NP cell trafficking and capability to reinstate enzymatic activity in vitro. Then, we successfully test our formulations in the Twitcher mouse. We report enzymatic activity measurements in the nervous system and in accumulation districts upon intraperitoneal injections, demonstrating activity recovery in the brain up to the unaffected mice level. Together, these results open new therapeutic perspectives for all LSDs with major CNS-involvement.

show abstract

“…To increase protein stability and to avoid initial burst release in the acidic internal pH environment, Zhou et al utilized ε–polylysine (ε-PL) as an anti-acidic agent and protein protectant during the preparation step of PLGA nanoparticles for protein delivery [95]. The cationic ε-PL was physically bound with negatively charged proteins such as BSA, and lactosylated PLGA (Lac-PLGA) was incorporated with the complex via nanoprecipitation.…”

Section: Nanoparticle-mediated Protein Deliverymentioning

confidence: 99%

Nanotechnology for protein delivery: Overview and perspectives

Shi

et al. 2016

Journal of Controlled Release

320

236

View full text Add to dashboard Cite

Protein-based therapeutics have made a significant impact in the treatment of a variety of important human diseases. However, given their intrinsically vulnerable structure and susceptibility to enzymatic degradation, many therapeutic proteins such as enzymes, growth factors, hormones, and cytokines suffer from poor physicochemical/biological stability and immunogenicity that may limit their potential benefits, and in some cases limit their utility. Furthermore, when protein therapeutics are developed for intracellular targets, their internalization and biological activity may be limited by inefficient membrane permeability and/or endosomal escape. Development of effective protein delivery strategies is therefore essential to further enhance therapeutic outcomes to enable widespread medical applications. This review discusses the advantages and limitations of marketed and developmental-stage protein delivery strategies, and provides a focused overview of recent advances in nanotechnology platforms for the systemic delivery of therapeutic proteins. In addition, we also highlight nanoparticle-mediated non-invasive administration approaches (e.g., oral, nasal, pulmonary, and transdermal routes) for protein delivery.

show abstract

Lactosylated PLGA nanoparticles containing ϵ-polylysine for the sustained release and liver-targeted delivery of the negatively charged proteins

Cited by 22 publications

References 33 publications

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

Brain-targeted enzyme-loaded nanoparticles: A breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease

Nanotechnology for protein delivery: Overview and perspectives

Contact Info

Product

Resources

About